Enoxaparin sodium, originally developed by Rhone-Poulenc Rorer in France (later merged with Hoechst in Germany to form Sanofi), is a low molecular weight heparin sodium extracted from pig intestine mucosa, obtained by esterification of heparin benzyl sodium derivative, and then produced by alkali lysis of heparin sodium. Structurally, it is composed of many complex and undefined oligosaccharides. According to current knowledge, most oligosaccharides have 4-enolpyranose acid at the non-reducing end of the sugar chain, and 1, 6-dehydrated structure at the reducing end of the sugar chain accounts for 15-25% of the total sugar.
Heparins Manufacturer of enoxaparin sodium
Enoxaparin has a mean weight molecular weight of 3800 * 5000, a weight percentage of oligosaccharides with molecular weight less than 2000 * 20%, a weight percentage of 68 * 82% for oligosaccharides with molecular weight less than 2000 * 8000, an antituberculous factor titer of 90 * 125IU/dry weight, The ratio of anti-tuberculosis to anti-tuberculosis was 3.3 * 5.3.
Heparins Manufacturer: mechanism
Heparin slows or prevents blood clotting in vitro and in vivo. Its mechanism of action is very complex and it affects many links in the coagulation process.
Its functions are as follows:
① Inhibit the formation and function of thrombin activating enzyme, thus preventing prothrombin from becoming thrombin;
② In high concentration, it can inhibit thrombin and other coagulation factors and prevent fibrinogen from becoming fibrin;
③ It can prevent the agglutination and destruction of platelet Chemicalbook.
In addition, the anticoagulant effect of heparin sodium is related to the negatively charged sulfate radical in the molecule. Alkaline substances with positive charge, such as protamine or toluidine blue, can neutralize its negative charge, so it can inhibit its anticoagulant effect. Because heparin can activate and release lipoprotein esterase in the body, hydrolysis of chylomicron triglyceride and low density lipoprotein, it also has hypolipidemic effect.